Abstract-. Starting from an HTS derived hit 1, application of biostructural data facilitated rapid optimization to lead 22, a novel AMPA receptor modulator. This is the first demonstration of how structure based drug design can be exploited in an optimization program for a glutamate receptor
The -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are ionotropic glutamate receptors which are abundantly expressed in the central nervous system and are believed to facilitate the majority of fast excitatory amino acid neurotransmission. [1] The role of AMPA receptors appears to be critical to mediating synaptic plasticity and long-term potentiation (LTP), the use dependent enhancement in synaptic efficacy which is thought to encode various forms of learning and memory. AMPA receptor modulators have been shown to enhance LTP and are, therefore, under serious consideration as therapeutic agents for a range of neurological disorders including schizophrenia, Alzheimer's Disease, Parkinson's disease and ADHD. [2, 3] Subunits of the AMPA receptor are encoded by 4 distinct genes (GluA1 to 4), with each subunit comprising 4 domains: N-terminal, extracellular glutamate binding site (Ligand Binding domain, LBD), a transmembrane region and a C-terminal domain. [4] In the last decade or so, significant advances have been made in studying the three-dimensional structure of the AMPA receptor with structures reported from a construct relating to the LBD (S1S2) [5] and latterly the full-length receptor. [6] Our research efforts were aimed at the identification of a novel series of AMPA receptor positive modulators which are of potential utility in the treatment of the kinds of neurological disorders delineated above. Following a high-throughput screening campaign using a functional assay with GluA1 overexpressed in HEK cells [7] , we identified compound 1 ( Figure 1 ) as a hit with confirmed activity from a well characterized solid sample. Compounds were inactive in the absence of glutamate, thus confirming their allosteric nature.
While compound 1 represented a tractable chemotype amenable to optimization and was deemed to have satisfactory potency (pEC50 = 6.7), further in vitro profiling revealed a number of deficiencies that required attention. Specifically, measured solubility was low (< 1mg/L) and there were attendant issues with microsomal stability (Rat/human intrinsic clearance, CLi > 270 L/min/mg protein).
From the outset of the program, we had access to biostructural data using the isolated S1S2 LBD GluA2 construct [5] thus enabling an understanding of how our compounds interacted with the receptor. [8] Figure 1 depicts hit compound 1 in complex with the S1S2 LBD GluA2 construct. [9] Although our biological assay used the GluA1 receptor (wild type GluA2 is not permeable to calcium), in our hands x-ray crystallographic study of selected compounds in both GluA1 and GluA2 constructs showed the structures to be identical. [10] Given that structures could be more expediently obtained with GluA2, we selected this construct for routine examination. Modulators of the AMPA receptor bind remotely to the orthosteric site and essentially stabilize a protein-protein interaction between the receptor subunits of each ligand binding domain. [11] Analysis of our X-ray data revealed that the interactions made with the receptor were primarily hydrophobic in nature, with key contacts made at the distal ends of the molecule (CF3 moiety and tetrahydrobenzothiophene system). From consideration of the biostructural data, three principal regions of the molecule were targeted (shown in red, green and blue) in order to address the solubility & metabolism issues (Figure 1 ).
Modification of the tetrahydrobenzothiophene portion (shown in blue, Figure 1B ) was expected to reduce lipophilicity and concomitantly improve potency and reduce propensity for hepatic metabolism. However, it was also anticipated that modulatory activity at the AMPA receptor may be negatively impacted by such changes. Indeed, stripping back the fused cyclohexyl ring system to furnish e.g. compound 2 ( Table 1 ) resulted in around a 30 fold reduction in potency, albeit with improvement observed in solubility (2 showed kinetic solubility of 10 mg/L). Other truncated analogues (e.g. 3 and 4) showed a similar reduction in potency without any improvement in solubility. Retention of the fused ring system with incorporation of a heteroatom was next explored in order to attenuate lipophilicity. Compound 5 displayed promising activity at the receptor but lacked any appreciable degree of solubility (< 1 mg/L) or metabolic stability (human and rat Cli > 270 L/min/mg protein). Insertion of a basic amine (6) or introduction of a pendant alcohol (7) led to a more than ten-fold reduction in potency. In parallel, the contribution of the tetrahydroindazole system (shown in green, Figure 1B ) to AMPA modulatory activity was examined ( Table 2) . Deletion of the fused cyclohexyl ring (8) resulted in approximately a 30-fold reduction in potency presumably due to loss of a non-specific hydrophobic interaction. Activity could be partially restored by introduction of a 5-CF3 substituent (9), however again this was accompanied by low solubility and microsomal stability (Solubility < 1 mg/L, Cli (human) = 174 L/min/mg protein, Cli (rat) = 200 L/min/mg protein). A fully aromatic system (10) exhibited promising GluA1 activity, however, was again compromised by inadequate solubility (< 1 mg/L) and less than optimal microsomal stability (Cli (human) = 153 L/min/mg protein, Cli (rat) = 91 L/min/mg protein). As we expected from the biostructure of 1, having a correctly orientated trifluromethyl moiety is essential for activity. Replacement with a methyl (11) or altering the relative position (12) gave rise to inactive compounds. The most effective means of meeting our optimization goals emerged from modification of the amide region of 1. From consideration of the biostructural data, a hydrophilic pocket adjacent to the primary carboxamide motif (highlighted in red, Figure 1B ) could be accessed by suitably functionalized entities. We, therefore, focused our efforts in making modifications to this region. Intially, simple carboxamide derivatives were prepared (e.g. 13, 14, Table 3 ) which confirmed that substitution at this position would be tolerated.
Encouraged by these results, we next prepared a number of more functionalized derivatives with pendant solubilising groups. Evaluation of compound 15 in the GluA1 assay showed the compound had modest potency compared to our progenitor hit 1. However, it was sufficiently potent to obtain biostructural data ( Figure 2 ) which revealed that contact with an Asp residue at the side of the hydrophilic pocket could be further optimized. We hypothesized that either modification of the linker length, or removal of one or both of the N,Ndimethyl moieties could be beneficial to potency. In compound 15, the binding mode of the tetrahydroindazole region was essentially identical to that observed with the progenitor compound (1). In the series as a whole, compound 16 displayed the best balance of solubility (38 mg/L) and microsomal stability (human Cli = 17 L/min/mg protein, rat Cli = 77 L/min/mg protein). Permeability as measured by CaCo-2 was deemed to be low, however there was no indication of efflux (A-B = 34 nm/s, B-A = 55 nm/s). In vivo pharmacokinetics in Wistar rats (2 mg/kg i.v., 10 mg/kg p.o.) indicated moderate clearance & half life in the i.v. leg (Clp = 21 mL/min/kg, T1/2 = 3.2 h, Vss = 3.8 L/kg), however, as anticipated from the CaCo-2 data, observed oral bioavailability was low (7.7%). Brain to plasma ratio was low (0.05) which was reasoned to be a function of both the number of hydrogen bond donors and rotatable bonds present in the molecule.
X-ray crystallographic data on the complex of 16 with the S1S2 LBD revealed the binding mode was as anticipated based on our observations from compound 15 (Figure 3 ). The propylamine side chain was shown to project into the hydrophilic pocket as before, but now forming a salt-bridge with the sidechain of Asp 760. The biostructural data also suggested that conformationally constrained analogues of 16 could be accommodated in the hydrophilic region and this led to the design and synthesis of analogues 22-25 (Table 4) in an effort to improve brain penetration and oral bioavailability. Figure 3 . X-ray structure of 16 in complex with the S1S2 LBD of GluA2
Comparing 22 and 23 shows a preference for the (R) stereochemistry on the pyrrolidine ring system. This was consistent with our expectations based on the conformation of the propylamine moiety required to facilitate the salt-bridge with Asp 760. The azetidine analogues 24 and 25 show similar potencies at GluA1 compared to 22. However, measured oral bioavailability was still low (3.8%) indicating that conformational constraint alone was not sufficient to enhance this important parameter.
Synthetic approaches to the compounds discussed above are outlined in Schemes 1 to 3. Compounds 1-7 were prepared through a Gewald cyclisation [12] to prepare the requisite tertrahydrobenzothiophene systems (27) followed by HATU mediated coupling to furnish compounds 1 to 7. Compounds 8 to 12 were synthesized in a two step fashion from the available amino thiophene derivative 28 (Scheme 2). Acetylation with bromacetyl bromide followed by alkylation of the appropriate azole derivative furnished the requisite target molecules in an expedient fashion. 
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Scheme 2. Reagents and conditions: a) bromoacetyl bromide, Et3N, CH2Cl2, rt, 94%; b) azole derivative, NaH, DMF, 0° to rt, 14-49%.
Amide derivatives 13 to 25 were accessed as depicted in Scheme 3. Starting from cyclohexanone, Gewald cyclisation furnished the aminothiophene ester 30. Amide coupling provided intermediate 31 which was deprotected by acidolysis. Subsequent HATU mediated amide formation provided amides 13 to 15 and 20/21. In the case of 16 to 19 and 22 to 25, a Boc protected diamine derivative is employed in the coupling step with the desired amine unmasked in a final TFA deprotection step. In summary, we have demonstrated how hit compound 1 was rapidly optimized to improve physicochemical 
